Skip to main
  1. Stocks
  2. DBV Technologies SA Sponsored ADR
  3. Forecast
DBVT

DBVT Stock Forecast & Price Target

DBVT Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

DBV Technologies is supported by a clear regulatory catalyst path for Viaskin Peanut, with BLA acceptance for children aged 4–7 expected in 4Q26 and a potential Priority Review that could materially shorten timelines versus standard review. Its fundamental appeal is reinforced by strong commercial potential, including projected peak sales of about $3B, while the company’s $165.7M to $166M cash balance provides runway into 3Q27 and helps fund launch preparation. Although manufacturing and CMC issues at Fareva Amboise create near-term overhang, management says they are remediation-related rather than product-defect related, and the sequential toddler filing strategy could improve review efficiency and support broader approval momentum.

Bears say

DBV Technologies is facing a negative fundamental outlook because its lead peanut allergy program has been hit by delays in BLA submission for both children and toddlers, alongside new adverse findings in the COMFORT-TODDLER study and other R&D, regulatory, or commercial setbacks. The company also faces meaningful clinical and regulatory risk, since success in VITESSE is needed to support a BLA in 4–7-year-olds, while accelerated approval in 1–3-year-olds depends on a confirmatory trial after approval. Financially, DBV is expected to continue net losses at least until commercialization and likely through the early launch phase, with a need to raise additional capital that could dilute shareholders, while variable desensitization and uncertain real-world protection weaken the commercial case for Viaskin Peanut.

DBVT has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.

DBVT Analyst Forecast & Price Prediction

Get the latest DBVT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DBVT

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DBV Technologies SA Sponsored ADR (DBVT) Forecast

Analysts have given DBVT a Buy based on their latest research and market trends.

According to 4 analysts, DBVT has a Buy consensus rating as of Nov 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DBV Technologies SA Sponsored ADR (DBVT)


DBVT Analyst Forecast & Price Prediction

Get the latest DBVT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DBVT

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover DBVT stock data and trends